355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies

• Jing Ye,
• Neha Dixit,
• Mitchell Cairo,
• Nina Shah,
• Alan Tan,
• Lihua Budde,
• Craig Hofmeister,
• Andrew Cowan,
• Hayder Saeed,
• David Rizzieri,
• Gregory Orloff,
• Xue Snow Ge,
• Zachary Lee,
• Wildaliz Nieves,
• Haijun Ma,
• Takahiro Miyazaki,
• Loui Madakamutil,
• Krina Patel

Affiliations

Jing Ye

7University of Michigan, Ann Arbor, MI, USA

Neha Dixit

Aff2 grid.429615.dNodality 170 Harbor Way 94080 South San Francisco CA USA

Mitchell Cairo

Aff14 grid.260917.b000000010728151XNew York Medical College at Maria Fareri Children’s Hospital 100 Woods Road 10595 Valhalla New York USA

Nina Shah

1 Division of Hematology-Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA

Alan Tan

2Rush University Medical Center, Chicago, IL, USA

Lihua Budde

3City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Craig Hofmeister

4Winship Cancer Institute of Emory University, Atlanta, GA, USA

Andrew Cowan

5University of Washington, Seattle, WA, USA

Hayder Saeed

6H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL, USA

David Rizzieri

9Duke University School of Medicine, Durham, NC, USA

Gregory Orloff

10Virginia Cancer Specialists, Fairfax, VA, USA

Xue Snow Ge

11Nektar Therapeutics, San Francisco, CA, USA

Zachary Lee

11Nektar Therapeutics, San Francisco, CA, USA

Wildaliz Nieves

11Nektar Therapeutics, San Francisco, CA, USA

Haijun Ma

11Nektar Therapeutics, San Francisco, CA, USA

Takahiro Miyazaki

11Nektar Therapeutics, San Francisco, CA, USA

Loui Madakamutil

11Nektar Therapeutics, San Francisco, CA, USA

Krina Patel

12The University of Texas MD Anderson Cancer Center, Houston, TX, USA